Suwen Chen
Jinan, 250011, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammation.
Journal: Chemico-biological interactions
Published: August 21, 2024
The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of Atherosclerosis.
Journal: Journal of cardiovascular pharmacology and therapeutics
Published: April 24, 2024
Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway.
Journal: International immunopharmacology
Published: April 13, 2024
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1/PGC-1α pathway.
Journal: European journal of pharmacology
Published: March 23, 2024
Hesperitin prevents non-alcoholic steatohepatitis by modulating mitochondrial dynamics and mitophagy via the AMPKα-Drp1/PINK1-Parkin signaling pathway.
Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids
Published: November 20, 2023
Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: September 21, 2023
Association between gastroesophageal reflux disease and stroke: a bidirectional Mendelian randomization study.
Journal: Frontiers in neurology
Published: September 15, 2023
Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials.
Journal: Phytotherapy research : PTR
Published: July 31, 2023
Mechanism of Action and Related Natural Regulators of Nrf2 in Nonalcoholic Fatty Liver Disease.
Journal: Current drug delivery
Published: May 15, 2023
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Journal: European journal of pharmacology
Published: April 06, 2023
Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.
Journal: Drug design, development and therapy
Published: August 20, 2022
Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo.
Journal: Frontiers in pharmacology
Published: August 11, 2022
Last Updated: 09/26/2026